AUS
NZ
UK
CA
USA
IND
Healthcare
CSL (ASX:CSL) Shares Hit Multi-Year Low Amid Revised Growth Outlook
October 28, 2025 05:43 PM AEDT| By SamCSL (ASX:CSL) adjusts its multi-year growth forecast, prompting investor scrutiny and renewed attention to the healthcare sector within the ASX 200 index.
CSL Vaccine Setback Jolts ASX Healthcare Stocks
October 28, 2025 04:51 PM AEDT| By SamThe article explores CSL Limited’s (ASX:CSL) vaccine challenges and their impact on the broader ASX healthcare landscape, while examining what’s next for Australia’s leading biotech giant.
CSL (ASX:CSL) Faces Guidance Revision Amid US Vaccination Decline
October 28, 2025 03:32 PM AEDT| By SamCSL (ASX:CSL) revises guidance amid lower US vaccination rates and delays its Seqirus demerger, signalling broader strategic recalibration across the ASX healthcare landscape.
CSL Ltd (ASX:CSL): Assessing True Value in Today’s Market
October 27, 2025 04:57 PM AEDT| By SamExplore how CSL Ltd (ASX:CSL) shapes investor confidence in the ASX stock market with insights into its business fundamentals and long-term growth potential.
Vitasora Health (ASX:VHL) Expands US via Evolent Care
October 24, 2025 02:08 PM AEDT| By SamVitasora Health expands its US operations through an enhanced partnership with Evolent Care, aiming to scale Connected Care services nationwide and strengthen its path to profitability.
FDA Fast Track for NNZ-2591: Boost for Neuren (ASX:NEU)?
October 23, 2025 02:41 PM AEDT| By SamNeuren Pharmaceuticals (ASX:NEU) gains FDA Fast Track for NNZ-2591, highlighting potential regulatory acceleration, clinical progress, and implications for the ASX stock market and short selling trends.
Explore ResMed (ASX:RMD) in the Dynamic ASX Stock Market
October 23, 2025 02:27 PM AEDT| By SamIn-depth look at ResMed (ASX:RMD) in the ASX stock market, highlighting healthcare innovation, sector stability, and investment trends.
Lumos Diagnostics (ASX:LDX) Speeds Up US Expansion
October 23, 2025 01:00 PM AEDT| By SamLumos Diagnostics (ASX:LDX) strengthens US market momentum with FebriDx® rollout, regulatory progress, and strategic service-driven innovation.
CSL & Pro Medicus Ltd Insights: Key ASX Stocks Worth Watching
October 22, 2025 06:17 PM AEDT| By SamA deep dive into CSL (ASX:CSL) and Pro Medicus Ltd (ASX:PME), highlighting their operations, market trends, and position in the ASX stock market.
CSL & Pro Medicus: Health Giants Under the ASX 200 Spotlight
October 22, 2025 06:01 PM AEDT| By SamCSL Ltd (ASX:CSL) and Pro Medicus Ltd (ASX:PME) drive innovation across biotechnology and digital healthcare, reinforcing Australia’s leadership within the ASX 200 through science, technology, and sustainable growth.
BlinkLab (ASX:BB1) Launches Dx 1 for Neuro Diagnostics
October 22, 2025 03:07 PM AEDT| By SamBlinkLab (ASX:BB1) advances child neurodevelopment diagnostics with Dx 1, demonstrating high accuracy and preparing for FDA trials.
Compumedics Limited’s Growth Story Sparks Market Attention
October 17, 2025 06:36 PM AEDT| By SamCompumedics Limited (ASX:CMP) gains investor focus as its innovation-driven growth story unfolds within Australia’s evolving medical technology landscape, reflecting broader optimism across the healthcare and diagnostic sectors.
Doctor Care Anywhere (ASX:DOC) Moves Toward Profitability Milestone
October 17, 2025 05:41 PM AEDT| By SamDoctor Care Anywhere (ASX:DOC) advances in digital healthcare, narrowing losses and nearing profitability, reflecting growing confidence in technology-driven medical services within the evolving ASX-listed healthcare landscape.
Orthocell (ASX:OCC) Expands US Remplir Launch Strategically
October 17, 2025 11:34 AM AEDT| By SamOrthocell strengthens US expansion of Remplir through a major placement, boosting its regenerative medicine pipeline and global commercialisation strategy.
TrivarX Expands Early Brain Cancer Detection with Stabl-Im
October 16, 2025 01:39 PM AEDT| By SamTrivarX (ASX:TRI) advances brain cancer diagnostics with Stabl-Im acquisition, offering non-invasive MRI-based detection and strengthening its position in neurological and oncology markets.
Ansell (ASX:ANN) Performance: Key Investor Insights
October 16, 2025 11:15 AM AEDT| By SamAn in-depth analysis of Ansell (ASX:ANN) focusing on return on capital employed, reinvestment trends, and implications for investors in the ASX market.
Cochlear (ASX:COH) Shares: 6 Must-Know Investor Metrics
October 15, 2025 05:44 PM AEDT| By SamExplore Cochlear Ltd (ASX:COH) shares with key metrics, revenue trends, profitability, and financial health insights for investors in the ASX stock market and ASX200 index.
Biotron (ASX:BIT) Strengthens Pipeline with Sedarex Acquisition and Capital Raising
October 15, 2025 04:06 PM AEDT| By SamBiotron (ASX:BIT) acquires Sedarex, a next-gen anaesthetic, backed by a capital raising to advance development and diversify its clinical pipeline in the ASX stock market.
Biotech Momentum on the ASX: Nexsen’s Dynamic Debut and Sector Revival
October 14, 2025 02:33 PM AEDT| By SamNexsen (ASX:NXN) energises the ASX biotech scene with innovative diagnostics, joined by Tetratherix, Clarity Pharmaceuticals, and Audeara driving breakthroughs across healthcare, imaging, and hearing technology in Australia’s dynamic life sciences se...
Ramsay Health Care’s Struggles Reflect Deeper Industry Pressures in ASX 200
October 10, 2025 05:45 PM AEDT| By SamAGM season heats up for Australian investors as top ASX ordinaries stocks prepare for updates. Companies like (ASX:ABB) are expected to draw strong market attention amid upbeat ASX 200 sentiment.
Advertise your brand on Kalkine Media